Showing results (441-450 of 525) with videos related to
Sort By:
Pageof 53
The Journal of Experimental Medicine|April 7, 2010
Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokinesM Anthony Moody, Hua-Xin Liao, S Munir Alam, et al.AIDS (London, England)|December 5, 2023
The immunogenicity of an HIV-1 Gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapyJeffrey M Jacobson, Barbara K Felber, Huichao Chen, et al.The Journal of Infectious Diseases|October 5, 2023
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120Zvavahera Mike Chirenje, Fatima Laher, One Dintwe, et al.PLOS Global Public Health|September 20, 2024
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trialVimla Naicker, Fatima Laher, Linda-Gail Bekker, et al.Plos Pathogens|March 13, 2020
Engagement of monocytes, NK cells, and CD4+ Th1 cells by ALVAC-SIV vaccination results in a decreased risk of SIVmac251 vaginal acquisitionGiacomo Gorini, Slim Fourati, Monica Vaccari, et al.The Journal of Clinical Investigation|October 8, 2019
Antibody Fc effector functions and IgG3 associate with decreased HIV-1 riskScott D Neidich, Youyi Fong, Shuying S Li, et al.Medrxiv : the Preprint Server for Health Sciences|June 5, 2026
A phase 1 randomized controlled trial to evaluate the safety and immunogenicity of a HIV monomeric gp120 protein B-cell lineage targeting HIV vaccine in healthy adultsJames J Kobie, Wilton B Williams, William O Hahn, et al.Journal of Virology|November 24, 2012
Antigenicity and immunogenicity of RV144 vaccine AIDSVAX clade E envelope immunogen is enhanced by a gp120 N-terminal deletionS Munir Alam, Hua-Xin Liao, Georgia D Tomaras, et al.Medrxiv : the Preprint Server for Health Sciences|January 23, 2024
A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087)Stephen R Walsh, Cynthia L Gay, Shelly T Karuna, et al.Immunity|December 20, 2014
Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conservedKevin Wiehe, David Easterhoff, Kan Luo, et al.Pageof 53